Using cost-effectiveness analysis for formulary decision making: from theory into practice.
The growth of expenditures on healthcare and pharmaceutical products is a concern to third-party payers because of the absence of market discipline (price signals that consumers face).  Cost-effectiveness analysis is a method that allows third-party payers to systematically make judgements about the 'value for money' of these products.  It moves beyond simple unit price comparisons of alternate interventions/products to consider the full stream of relevant cost and benefits.  As formulary committees begin to adopt the systematic use of cost-effectiveness analyses to inform the debate, the exercise will move from an academic to a more practical application.  This transition will require several important changes including defining the purpose of cost-effectiveness analysis, measurement of outcomes and data, format of reports, and contractual arrangements between the pharmaceutical industry and analysts.  As more 'real world' experience is gained in the practical application of cost-effectiveness analysis, the quality of data will improve as will its value as an aid to decision making.
Departments of Health Administration and Medicine, University of Toronto, Ontario, Canada.
A S
AS
Detsky
D003362:Cost-Benefit Analysis / Q000379:methods / Q000639:trends; D003657:Decision Making; D017850:Economics, Pharmaceutical; D005544:Forecasting; D005569:Formularies as Topic; D006801:Humans; D007349:Insurance, Health, Reimbursement; D017063:Outcome Assessment, Health Care